Neuroimaging of Phakomatoses

Seminars in Pediatric Neurology

Volumn 13, Issue 1, 2006, Pages 48-62

  Lin, Doris D M ^a   Barker, Peter B ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

brain; computed tomography; magnetic resonance imaging; neurocutaneous; neurofibromatosis; perfusion; phakomatosis; spectroscopy; spine; Sturge Weber; tuberous sclerosis; von Hippel Lindau

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; MERLIN; NEUROFIBROMIN;

ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ECTODERM; EYE; GENE MUTATION; HUMAN; NEUROFIBROMATOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PHAKOMATOSIS; POSITRON EMISSION TOMOGRAPHY; STURGE WEBER SYNDROME; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

CENTRAL NERVOUS SYSTEM; DIAGNOSTIC IMAGING; HUMANS; NEUROCUTANEOUS SYNDROMES; SKIN; SPINAL CORD;

EID: 33745509036     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2006.01.011     Document Type: Article

References (88)

1. Korf B.R. The phakomatoses. Neuroimaging Clin N Am 14 (2004) 139-148
2. Friedman J.M. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89 (1999) 1-6
3. Cichowski K., and Jacks T. NF1 tumor suppressor gene function. narrowing the GAP. Cell 104 (2001) 593-604
4. World Health Organization Classification of Tumors, Pathology & Geneics (2000), IARC Press, Lyon
5. Friedrich R.E., Korf B., Funsterer C., et al. Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images. Anticancer Res 23 (2003) 949-952
6. Rodriguez D., and Young Poussaint T. Neuroimaging findings in neurofibromatosis type 1 and 2. Neuroimaging Clin N Am 14 (2004) 149-170
7. Evans D.G., Baser M.E., McGaughran J., et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39 (2002) 311-314
8. Solomon S.B., Semih Dogan A., Nicol T.L., et al. Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 26 (2001) 525-528
9. Cardona S., Schwarzbach M., Hinz U., et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29 (2003) 536-541
10. Ferner R.E., Lucas J.D., O'Doherty M.J., et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 68 (2000) 353-357
11. Friedman J.M., and Birch P.H. Type 1 neurofibromatosis. a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70 (1997) 138-143
12. Balcer L.J., Liu G.T., Heller G., et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas. relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 131 (2001) 442-445
13. Griffiths P.D., Blaser S., Mukonoweshuro W., et al. Neurofibromatosis bright objects in children with neurofibromatosis type 1. a proliferative potential?. Pediatrics 104 (1999) e49
14. Itoh T., Magnaldi S., White R.M., et al. Neurofibromatosis type 1. the evolution of deep gray and white matter MR abnormalities. AJNR Am J Neuroradiol 15 (1994) 1513-1519
15. Van Es S., North K.N., McHugh K., et al. MRI findings in children with neurofibromatosis type 1. a prospective study. Pediatr Radiol 26 (1996) 478-487
16. DiPaolo D.P., Zimmerman R.A., Rorke L.B., et al. Neurofibromatosis type 1. pathologic substrate of high-signal-intensity foci in the brain. Radiology 195 (1995) 721-724
17. Kraut M.A., Gerring J.P., Cooper K.L., et al. Longitudinal evolution of unidentified bright objects in children with neurofibromatosis-1. Am J Med Genet A 129 (2004) 113-119
18. Denckla M.B., Hofman K., Mazzocco M.M., et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 67 (1996) 98-102
19. North K.N., Riccardi V., Samango-Sprouse C., et al. Cognitive function and academic performance in neurofibromatosis. 1. consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 48 (1997) 1121-1127
20. Cutting L.E., Koth C.W., Burnette C.P., et al. Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1. J Child Neurol 15 (2000) 157-160
21. Evans D.G. Neurofibromatosis type 2. genetic and clinical features. Ear Nose Throat J 78 (1999) 97-100
22. Evans D.G., Lye R., Neary W., et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry 66 (1999) 764-767
23. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. Arch Neurol 51 (1994) 201-207
24. Baser M.E., Friedman J.M., Wallace A.J., et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59 (2002) 1759-1765
25. Rouleau G.A., Merel P., Lutchman M., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363 (1993) 515-521
26. Trofatter J.A., MacCollin M.M., Rutter J.L., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72 (1993) 791-800
27. Smirniotopoulos J.G., and Murphy F.M. The phakomatoses. AJNR Am J Neuroradiol 13 (1992) 725-746
28. Patronas N.J., Courcoutsakis N., Bromley C.M., et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2. MR imaging findings and correlation with genotype. Radiology 218 (2001) 434-442
29. Mautner V.F., Friedrich R.E., von Deimling A., et al. Malignant peripheral nerve sheath tumours in neurofibromatosis type 1. MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology 45 (2003) 618-625
30. Thiele E.A. Managing epilepsy in tuberous sclerosis complex. J Child Neurol 19 (2004) 680-686
31. Prather P., and de Vries P.J. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol 19 (2004) 666-674
32. Goh S., Kwiatkowski D.J., Dorer D.J., et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 65 (2005) 235-238
33. Roach E.S., and Sparagana S.P. Diagnosis of tuberous sclerosis complex. J Child Neurol 19 (2004) 643-649
34. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277 (1997) 805-808
35. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome. 16 Tuberous Sclerosis Consortium. Cell 75 (1993) 1305-1315
36. Narayanan V. Tuberous sclerosis complex. genetics to pathogenesis. Pediatr Neurol 29 (2003) 404-409
37. van Slegtenhorst M., Nellist M., Nagelkerken B., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7 (1998) 1053-1057
38. Christophe C., Sekhara T., Rypens F., et al. MRI spectrum of cortical malformations in tuberous sclerosis complex. Brain Dev 22 (2000) 487-493
39. DiMario Jr. F.J. Brain abnormalities in tuberous sclerosis complex. J Child Neurol 19 (2004) 650-657
40. Griffiths P.D., and Martland T.R. Tuberous sclerosis complex. the role of neuroradiology. Neuropediatrics 28 (1997) 244-252
41. Shepherd C.W., Houser O.W., and Gomez M.R. MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. AJNR Am J Neuroradiol 16 (1995) 149-155
42. Roach E.S., Gomez M.R., and Northrup H. Tuberous sclerosis complex consensus conference. revised clinical diagnostic criteria. J Child Neurol 13 (1998) 624-628
43. Iwasaki S., Nakagawa H., Kichikawa K., et al. MR and CT of tuberous sclerosis. linear abnormalities in the cerebral white matter. AJNR Am J Neuroradiol 11 (1990) 1029-1034
44. Griffiths P.D., Bolton P., and Verity C. White matter abnormalities in tuberous sclerosis complex. Acta Radiol 39 (1998) 482-486
45. Christophe C., Bartholome J., Blum D., et al. Neonatal tuberous sclerosis. US, CT, and MR diagnosis of brain and cardiac lesions. Pediatr Radiol 19 (1989) 446-448
46. Smirniotopoulos J.G. Neuroimaging of phakomatoses. Sturge-Weber syndrome, tuberous sclerosis, von Hippel-Lindau syndrome. Neuroimaging Clin N Am 14 (2004) 171-183
47. Griffiths P.D., Gardner S.A., Smith M., et al. Hemimegalencephaly and focal megalencephaly in tuberous sclerosis complex. AJNR Am J Neuroradiol 19 (1998) 1935-1938
48. Tarasow E., Kubas B., and Walecki J. MR proton spectroscopy in patients with CNS involvement in Bourneville's disease. Med Sci Monit 7 (2001) 762-765
49. Mukonoweshuro W., Wilkinson I.D., and Griffiths P.D. Proton MR spectroscopy of cortical tubers in adults with tuberous sclerosis complex. AJNR Am J Neuroradiol 22 (2001) 1920-1925
50. Yapici Z., Dincer A., and Eraksoy M. Proton spectroscopic findings in children with epilepsy owing to tuberous sclerosis complex. J Child Neurol 20 (2005) 517-522
51. Garaci F.G., Floris R., Bozzao A., et al. Increased brain apparent diffusion coefficient in tuberous sclerosis. Radiology 232 (2004) 461-465
52. Karadag D., Mentzel H.J., Gullmar D., et al. Diffusion tensor imaging in children and adolescents with tuberous sclerosis. Pediatr Radiol 35 (2005) 980-983
53. Jansen F.E., Braun K.P., van Nieuwenhuizen O., et al. Diffusion-weighted magnetic resonance imaging and identification of the epileptogenic tuber in patients with tuberous sclerosis. Arch Neurol 60 (2003) 1580-1584
54. Sieg K.G., Harty J.R., Simmons M., et al. Tc-99m HMPAO SPECT imaging of the central nervous system in tuberous sclerosis. Clin Nucl Med 16 (1991) 665-667
55. Rintahaka P.J., and Chugani H.T. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 12 (1997) 42-52
56. Moore G.J., Slovis T.L., and Chugani H.T. Proton magnetic resonance spectroscopy in children with Sturge-Weber syndrome. J Child Neurol 13 (1998) 332-335
57. Kagawa K., Chugani D.C., Asano E., et al. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET). J Child Neurol 20 (2005) 429-438
58. Maria B.L., Hoang K.B., Robertson R.L., et al. Imaging Brain Structure and Function in Sturge-Weber Syndrome (1999), Sturge-Weber Foundation, Mt Freedom, NJ
59. Comi A.M. Pathophysiology of Sturge-Weber syndrome. J Child Neurol 18 (2003) 509-516
60. Thomas-Sohl K.A., Vaslow D.F., and Maria B.L. Sturge-Weber syndrome. a review. Pediatr Neurol 30 (2004) 303-310
61. Enjolras O., Riche M.C., and Merland J.J. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 76 (1985) 48-51
62. Roach E.S. Neurocutaneous syndromes. Pediatr Clin North Am 39 (1992) 591-620
63. Griffiths P.D. Sturge-Weber syndrome revisited. the role of neuroradiology. Neuropediatrics 27 (1996) 284-294
64. Marti-Bonmati L., Menor F., Poyatos C., et al. Diagnosis of Sturge-Weber syndrome. comparison of the efficacy of CT and MR imaging in 14 cases. AJR Am J Roentgenol 158 (1992) 867-871
65. Wasenko J.J., Rosenbloom S.A., Duchesneau P.M., et al. The Sturge-Weber syndrome. comparison of MR and CT characteristics. AJNR Am J Neuroradiol 11 (1990) 131-134
66. Bebin E.M., and Gomez M.R. Prognosis in Sturge-Weber disease. comparison of unihemispheric and bihemispheric involvement. J Child Neurol 3 (1988) 181-184
67. Griffiths P.D., Coley S.C., Romanowski C.A., et al. Contrast-enhanced fluid-attenuated inversion recovery imaging for leptomeningeal disease in children. AJNR Am J Neuroradiol 24 (2003) 719-723
68. Reichenbach J.R., Barth M., Haacke E.M., et al. High-resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr 24 (2000) 949-957
69. Reichenbach J.R., Jonetz-Mentzel L., Fitzek C., et al. High-resolution blood oxygen-level dependent MR venography (HRBV). a new technique. Neuroradiology 43 (2001) 364-369
70. Mentzel H.J., Dieckmann A., Fitzek C., et al. Early diagnosis of cerebral involvement in Sturge-Weber syndrome using high-resolution BOLD MR venography. Pediatr Radiol 35 (2005) 85-90
71. Griffiths P.D., Boodram M.B., Blaser S., et al. 99mTechnetium HMPAO imaging in children with the Sturge-Weber syndrome. a study of nine cases with CT and MRI correlation. Neuroradiology 39 (1997) 219-224
72. Bar-Sever Z., Connolly L.P., Barnes P.D., et al. Technetium-99m-HMPAO SPECT in Sturge-Weber syndrome. J Nucl Med 37 (1996) 81-83
73. Reid D.E., Maria B.L., Drane W.E., et al. Central nervous system perfusion and metabolism abnormalities in Sturge-Weber syndrome. J Child Neurol 12 (1997) 218-222
74. Maria B.L., Neufeld J.A., Rosainz L.C., et al. Central nervous system structure and function in Sturge-Weber syndrome. evidence of neurologic and radiologic progression. J Child Neurol 13 (1998) 606-618
75. Lin D.D., Barker P.B., Kraut M.A., et al. Early characteristics of Sturge-Weber syndrome shown by perfusion MR imaging and proton MR spectroscopic imaging. AJNR Am J Neuroradiol 24 (2003) 1912-1915
76. Breiter S.N., Arroyo S., Mathews V.P., et al. Proton MR spectroscopy in patients with seizure disorders. AJNR Am J Neuroradiol 15 (1994) 373-384
77. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 361 (2003) 2059-2067
78. Sims K.B. Von Hippel-Lindau disease. gene to bedside. Curr Opin Neurol 14 (2001) 695-703
79. Maher E.R., Iselius L., Yates J.R., et al. Von Hippel-Lindau disease. a genetic study. J Med Genet 28 (1991) 443-447
80. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
81. Barry R.E., and Krek W. The von Hippel-Lindau tumour suppressor. a multi-faceted inhibitor of tumourigenesis. Trends Mol Med 10 (2004) 466-472
82. Choyke P.L., Glenn G.M., Walther M.M., et al. von Hippel-Lindau disease. genetic, clinical, and imaging features. Radiology 194 (1995) 629-642
83. Slater A., Moore N.R., and Huson S.M. The natural history of cerebellar hemangioblastomas in von Hippel-Lindau disease. AJNR Am J Neuroradiol 24 (2003) 1570-1574
84. Wanebo J.E., Lonser R.R., Glenn G.M., et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98 (2003) 82-94
85. Choo D., Shotland L., Mastroianni M., et al. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg 100 (2004) 480-487
86. Lonser R.R., Kim H.J., Butman J.A., et al. Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med 350 (2004) 2481-2486
87. Devaney K.O., Ferlito A., and Rinaldo A. Endolymphatic sac tumor (low-grade papillary adenocarcinoma) of the temporal bone. Acta Otolaryngol 123 (2003) 1022-1026
88. Kim H.J., Butman J.A., Brewer C., et al. Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease. implications for their natural history, diagnosis, and treatment. J Neurosurg 102 (2005) 503-512